257 related articles for article (PubMed ID: 14506161)
1. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
4. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
5. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
[TBL] [Abstract][Full Text] [Related]
6. Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
Park CM; Lee WY; Chun HK; Cho YB; Yun HR; Heo JS; Yun SH; Kim HC
J Surg Oncol; 2010 Jan; 101(1):22-7. PubMed ID: 19798689
[TBL] [Abstract][Full Text] [Related]
7. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
8. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E
Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
Mauritz R; Giovannetti E; Beumer IJ; Smid K; Van Groeningen CJ; Pinedo HM; Peters GJ
Clin Colorectal Cancer; 2009 Jul; 8(3):146-54. PubMed ID: 19632929
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
Ren DN; Kim IY; Koh SB; Chang SJ; Eom M; Yi SY; Seong SH; Kim MD; Bronner MP; Cho MY
J Surg Oncol; 2009 Dec; 100(7):546-52. PubMed ID: 19722231
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase pharmacogenetics in colorectal cancer.
Marsh S; McLeod HL
Clin Colorectal Cancer; 2001 Nov; 1(3):175-8; discussion 179-81. PubMed ID: 12450432
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
13. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.
Ishida Y; Kawakami K; Tanaka Y; Kanehira E; Omura K; Watanabe G
Anticancer Res; 2002; 22(5):2805-9. PubMed ID: 12530000
[TBL] [Abstract][Full Text] [Related]
14. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
Iacopetta B; Grieu F; Joseph D; Elsaleh H
Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
[TBL] [Abstract][Full Text] [Related]
15. Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
Prall F; Ostwald C; Schiffmann L; Barten M
Oncol Rep; 2007 Jul; 18(1):203-9. PubMed ID: 17549369
[TBL] [Abstract][Full Text] [Related]
16. [Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
Kiss-László Z; Nagy B; Thurzó L; Szabó J
Magy Onkol; 2006; 50(1):33-7. PubMed ID: 16617381
[TBL] [Abstract][Full Text] [Related]
17. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
[TBL] [Abstract][Full Text] [Related]
18. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
Merkelbach-Bruse S; Hans V; Mathiak M; Sanguedolce R; Alessandro R; Rüschoff J; Büttner R; Houshdaran F; Gullotti L
Oncol Rep; 2004 Apr; 11(4):839-43. PubMed ID: 15010882
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer.
Chen J; Hunter DJ; Stampfer MJ; Kyte C; Chan W; Wetmur JG; Mosig R; Selhub J; Ma J
Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):958-62. PubMed ID: 14578129
[TBL] [Abstract][Full Text] [Related]
20. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
Ichikawa W; Takahashi T; Suto K; Sasaki Y; Hirayama R
Clin Cancer Res; 2006 Jul; 12(13):3928-34. PubMed ID: 16818689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
